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Thin ﬁlamentPrevious structural studies indicated a special functional role for an acidic region composed of residues 1–10
in the unique N-terminal peptide of cardiac troponin I (cTnI). Employing LC–MS/MS, we determined the
presence of phosphorylation sites at S5/S6 in cTnI from wild type mouse hearts as well as in hearts of mice
chronically expressing active protein kinase C-ε (PKCε) and exhibiting severe dilated cardiomyopathy
(DCM). To determine the functional signiﬁcance of these phosphorylations, we cloned and expressed
wild-type cTnI, (Wt), and cTnI variants expressing pseudo-phosphorylation cTnI-(S5D), cTnI(S6D), as well
as cTnI(S5A) and cTnI(S6A). We exchanged native Tn of detergent-extracted (skinned) ﬁber bundles with
Tn reconstituted with the variant cTnIs and measured tension and cross-bridge dynamics. Compared to
controls, myoﬁlaments controlled by cTnI with pseudo-phosphorylation (S6D) or Ala substitution (S6A)
demonstrated a signiﬁcant depression in maximum tension, ATPase rate, and ktr, but no change in half-
maximally activating Ca2+. In contrast, pseudo-phosphorylation at position 5 (S5D) had no effects, although
S5A induced an increase in Ca2+-sensitivity with no change in maximum tension or ktr. We further tested the
impact of acidic domain modiﬁcations on myoﬁlament function in studies examining the effects of cTnI(A2V),
a mutation linked to DCM. This mutation signiﬁcantly altered the inhibitory activity of cTnI as well as
cooperativity of activation of myoﬁlament tension, but not when S23/S24 were pseudo-phosphorylated. Our
data indicate a new functional and pathological role of amino acidmodiﬁcations in the N-terminal acidic domain
of cTnI that is modiﬁed by phosphorylations at cTnI(S23/S24). This article is part of a Special Issue entitled:
Cardiomyocyte Biology: Cardiac Pathways of Differentiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
In experiments reported here, we investigated the functional
signiﬁcance of modiﬁcations in an acidic region composed of residues
1–10 in the unique N-terminal peptide of cardiac troponin I (cTnI).
cTnI, in conjunction with the Ca-receptor, cardiac troponin C (cTnC),
the scaffolding protein, cardiac troponin T (cTnT), and tropomyosin
(Tm), functions in a molecular mechanism to switch on and modulateoponin I; cTnT, cardiac tropo-
, switch peptide; Ip, inhibitory
yocyte Biology: Cardiac Path-
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rights reserved.sarcomeric force and shortening [1,2]. In relaxed sarcomeres, two
basic domains (an inhibitory peptide, Ip, and a second actin binding
region [3,4]) of cTnI are tethered to actin and together with the
N-terminal extension of cTnT, hold Tm in a position to block force
generating cross-bridges from reacting with thin ﬁlament actins.
The actin-binding domains of cTnI ﬂank a switch peptide (SwP) that
binds to cTnC upon Ca-binding to its regulatory site [5,6]. This move-
ment of SwP induces a relocation of the cTnI interaction with actin
thereby inducing a release of Tm from its blocking position and the
thin ﬁlament from inhibition.
Unique domains, especially the cTnI N-terminus consisting of ~30
amino acids are well known to control cardiac function [7–10]. Phos-
phorylation at S23/S24, which are substrates for several protein kinases,
especially protein kinase A (PKA) [11], depresses Ca-responsiveness of
myoﬁlament tension [2], increases the rate of myosin head binding to
thin ﬁlaments [12], and increases in thin ﬁlament sliding velocity in
the motility assay [13], but has no effect on maximum tension or open
and closed states of the thin ﬁlaments [12]. There are also highly
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icance of these residues has yet to be determined.
Results of recent studies have signiﬁcantly altered thinking re-
garding the role of the unique N-terminus in control of cardiac func-
tion [7,14,15]. The N-terminus did not resolve in the elucidation of
the core crystal structure of cTnI [16], but Howarth et al. [14] deter-
mined the NMR solution structure of cTnI (aa 1–32) and employed
bioinformatic analysis together with data from small angle X-ray
scattering experiments to model the N-terminal extension into the
core crystal structure of cTn. In the non-phosphorylated state, the
model demonstrated a close interaction between the N-terminal
extension with cTnC near L29 as previously shown in peptide-array
experiments [13]. The NMR solution structure also determined that
upon phosphorylation of S23/S24, cTnI undergoes a major conforma-
tional transition dependent on a hinge within cTnI-(aa 33–42).
Molecular docking of cTnI into the core structure indicated that this
structural transition induced close proximity between acidic residues
in the N-terminal extension (D3, E4, D7 and E11) with basic residues
in the inhibitory peptide and with the SwP. The acidic region (aa 1–10)
at the N-terminus, which is connected to the region housing S23/S24
by an extended poly-Pro II helix (aa 11–19), thus appeared to have a
previously unappreciated functional signiﬁcance based on an intra-
molecular interaction [7,17,18]. We [15] tested this idea by engineering
a Cys residue into cTnI at positions 5 and 19 and demonstrated cross-
linking of these sites to Met residues in the SwP of cTnI.
Following investigation of phosphorylation sites in mouse cTnI
employing liquid chromatography with tandem mass spectrometry
(LC–MS/MS), we discovered, as reported here, the presence of novel
phosphorylation sites at S5/S6 of cTnI. At the same time there have
been reports of the existence of these sites in human cTnI with evi-
dence that the relative phosphorylation at these sites decreases
with cardiac disorders such as dilated and hypertrophic cardiomyop-
athies [19]. To determine the signiﬁcance of phosphorylation in the
unique N-terminus of cTnI at either S5 or S6, we expressed cTnI
pseudo-phosphorylated at these sites, and determined their function-
al effects when exchanged into detergent-extracted (skinned) ﬁber
bundles. To further investigate the signiﬁcance of the acidic region
of the cTnI N-terminus, we also expressed cTnI(A2V), a mutant linked
to DCM, and determined its effects on myoﬁlament function [20]. Our
results indicate that phosphorylation and structural modiﬁcations
depress myoﬁlament tension and that the A2V mutation alters myo-
ﬁlament cooperative activation as well as responsiveness to phos-
phorylation of cTnI at S23/S24.
2. Methods
2.1. Animal model of dilated cardiomyopathy
Experiments using transgenic animals were conducted in accor-
dance with the Institutional Animal Care and Use Committee at the
University of Illinois and the National Institute of Health guidelines.
PKCε transgenic mice were generated via cardiac-speciﬁc expression
of constitutively active PKCε(A159E), driven by mouse α-myosin
heavy chain promoter on a FVB background as previously described
[21].
2.2. Protein puriﬁcation and reconstitution into Tn complex and
regulated myoﬁlaments
We expressed and puriﬁed recombinant mouse and human cTnI
(wild-type and variants as described in the results) employing
pET3d, mouse cTnT containing an N-terminal myc tag in pSBET, and
mouse and human cTnC in pET3d puriﬁed as described previously
[22–24]. Tn complex containing mouse cTnI, cTnT, and cTnC was
used in S5/6 experiments, while the complex containing human
cTnI with mouse cTnT and cTnC was used in the A2V experiments.Tn complex was reconstituted and veriﬁed as previously described
[23,25,26]. Actin was isolated from rabbit fast skeletal muscle acetone
powder and tropomyosin was prepared from bovine cardiac ether
powder as described previously [26]. Myosin-S1 was made by chymo-
tryptic digestion of rabbit psoas muscle myosin [23].
2.3. Mass spectrometry
Sarcomeric fractions were enriched from ventricular lysates of
12-month PKCε and FVB mice according to Scruggs et al. [27]. As a
preparatory step to enrich endogenous cTnI prior to mass spec-
trometry, sarcomeric proteins (1 mg) were separated in solution via
OFFGEL electrophoresis (Agilent Technologies) using a 24 cm, pH
7–10 IPG strip (Biorad) and the following focusing conditions:
8000 V, 64 kVh, 50 μA and 200 mW. To further enrich cTnI, OFFGEL
fractions containing cTnI were separated via 12% SDS-PAGE. cTnI
protein bands were excised and digested according to Deng et al.
[28]. LC–MS/MS with collision-induced dissociation (CID) fragmenta-
tion was performed on a linear trap quadrupole (LTQ) instrument
(ThermoFisher Scientiﬁc) integrated with a Surveyor nano-LC in-
strument. A PicoFrit C18 column (75 μm×10 cm, New Objective)
containing resin (Biobasic C18, 5 μm particle size, 300-Å pore size,
New Objective) was used. Electrospray ionization (ESI) conditions
for the LTQ were 190 °C capillary temperature, 2.0 kV spray voltage,
and a nano-LC source. Reverse-phase chromatography ﬂow rate was
5 μl/min for loading and 220 nl/min for separation (buffer A: 0.1%
formic acid, 2% acetonitrile; buffer B: 0.1% formic acid, 80% acetoni-
trile). Peptides were resolved as follows: time 0 min/2% B, time
100 min/50% B, time 110 min/100% B, time 120 min/100% B; time
121 min/2% B. The LTQ was operated in data-dependent mode; one
full MS scan was followed by ﬁve MS2 scans. Spectra were searched
against the International Protein Index mouse database (Version
3.47) using the Sequest algorithm (Bioworks Version 3.3). Search
parameters were set as follows: partial enzymatic digestion (trypsin);
two missed cleavages; 2.0 precursor tolerance; 1.0 fragment tolerance;
ﬁxed modiﬁcation of cysteine carbamidomethylation (+57 Da); and
variable modiﬁcations of methionine oxidation (+16 Da) and serine,
threonine, and tyrosine phosphorylation (+80 Da). Identiﬁed peptides
were ﬁltered according to the following criteria: Xcorr >2.5 (+2)
or >3.5 (+3). The reported peptides had a probability better than
95% (pb0.05) in Scaffold. Phosphorylation site(s) were identiﬁed in
two biological replicates.
2.4. Exchange of recombinant cTn into skinned left ventricular
ﬁber bundles
In studies of pseudo-phosphorylation and related variants of
cTnI(S5/S6), left ventricular papillary ﬁber bundles were freshly
dissected from male FVBN mouse hearts, aged 4–5 months, in
dissecting solution containing 100 mM BES, 10 mM EGTA, 6.57 mM
MgCl2, 10 mM creatine phosphate, 6.22 mM ATP, 2.5 μM pepstatin,
1 μM leupeptin, 50 μM PMSF, 5 mM NaN3, pH 7.0. Whole papillary
ﬁber bundles were then cut into strips 125–275 μm wide by 125–
275 μm deep and incubated in the above solution containing 1%
Triton X-100 at 4 °C for 2 h to allow complete skinning. Aluminum
T-clips were attached to both ends of the ﬁber preparations following
exchange of endogenous cTn for exogenous cTn. Fibers were exchanged
by overnight incubation at 4 °C in exchange buffer (200 mMKCl, 5 mM
MgCl2, 5 mM EGTA, 20 mM MOPS, 1 mM DTT, pH 6.5) containing
12–15 μM recombinant cTn (containing mouse cTnI), as previously
described [24]. A similar procedure using recombinant Tn complex
(containing human cTnI) was carried out in studies of the cTnI(A2V)
mutant and related variants described in the Results section with the
exception that female CD-1 mouse hearts aged 4–5 months were
used. Recombinant cTn complexes containing N-terminal myc-tagged
mouse cTnTwere used in the present study to allow for the quantiﬁcation
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[24]. Previous studies have demonstrated that myoﬁlament function is
not affected by the presence of the myc-tag [22,24].
2.5. Measurement of isometric tension, stiffness, ATPase, and ktr
Isometric tension and ATPase rate of skinned left ventricular ﬁber
bundles were simultaneously measured using experimental appara-
tus and methodology according to de Tombe and Steinen as described
in detail previously [29]. After mounting the ﬁbers, 1 cycle of activa-
tion was performed and the sarcomere length was adjusted to
2.2 μm using diffraction by He–Ne laser following the procedures de-
scribed by de Tombe and ter Keurs [30]. Sarcomere length remained
stable throughout the experimental protocol. Measurements of the
rate of force redevelopment (ktr) were carried out by a procedure
originated by Brenner and Eisenberg [31]. Other aspects of the proce-
dure were as described in detail by Chandra et al. [22]. The ﬁber bun-
dle was moved sequentially into relaxing solution, then into the
pre-activating solution, and ﬁnally into the experimental pCa solution
where isometric force, stiffness, ATPase, and ktr were determined.
After these parameters were measured, the ﬁber was returned to the
relaxing solution until force decreased to the pre-activation level,
followed by placement into the pre-activating solution in preparation
for the next activation. Each ﬁber bundle underwent 8–10 contractions,
with the ﬁrst and last contractions being in maximal activating solution,
pCa 4.5. Fibers were discarded if tension decreased by greater than 25%
of the initial activation. Steady-state ATPase rate was determined by an
enzyme-coupled ultraviolet light absorbance assay previously de-
scribed, in which ATP consumed by the muscle during contraction was
stoichiometrically linked to NAD+ formation. Calibration curves were
performed with each experimental contraction as previously described
[29]. The rate of force redevelopment, ktr, was measured in each pCa so-
lution by a protocol previously described by Hinken andMcDonald [32].
All mechanical experiments were performed at either 15° (A2V experi-
ments) or 20 °C (S5/6 experiments). Following mechanical measure-
ments, each ﬁber was stored at −8 °C for subsequent biochemical
analysis.
2.6. In-vitro PKA phosphorylation
Puriﬁed cTn containingWt, S6A, and S6D TnI variants was incubated
with 2.5 mM ATP for 30 min at 27 °C in 0.2 M KCl, 5 mM EGTA, 5 mM
MgCl2, 20 mM MOPS, 1 mM DTT, pH 6.5 or in the above solution and
0.025 U PKA (Sigma)/μg TnI. PKA treated and untreated cTn complexes
were dialyzed overnight in 0.1 M NaCl, 5 mM MgCl2, 0.1 mM CaCl2,
20 mM Tris, pH 8.0 prior to use in in-vitro ATPase assay as described
below. Phosphorylation of cTnI was conﬁrmed in samples by 12%
SDS-PAGE using ProQ Diamond stain (Invitrogen).
2.7. ATPase assay with reconstituted myoﬁlaments
In vitro ATPase assay was performed as described previously [33].
Myoﬁlaments were reconstituted using cTn complex containing PKA
treated and untreated cTnI (Wt, S6D, S6A), myosin S1, actin, and
tropomyosin and were dialyzed against 70 mM NaCl, 10 mM MgCl2,
40 mM MOPS, pH 7.0. Assay conditions contained 5 μM actin, 0.4 μM
tropomyosin, 0.2 μM S1, and 1 mM ATP with various concentrations
of cTn complex with a total reaction concentration of 35 mM NaCl,
5 mM MgCl2, 20 mM MOPS, pH 7.0. Reactions were performed in the
presence of Ca2+ (0.1 mM) or in its absence (2 mM EGTA), incubated
at 27 °C, andwere quenched in 0.2 M perchloric acid at 10 °C at various
times. Phosphate production was measured following incubation for
20 min at 27 °C with a malachite green assay [33,34] by spectrophoto-
metric absorbance at 655 nm. In studies with the cTnI (A2V) mutant
and related variants, the reaction mixture was the same as described
above except that actin, Tm, and myosin S-1 concentrations were 6, 1,and 0.5 μM respectively. ATPase was determined as described above
at 25 °C.
2.8. Solutions
Relaxing solution (pCa 10.0), contained 100 mM BES, 1 mM free
Mg2+, 5 mMMgATP, 10 mM EGTA, 48.95 mM potassium propionate,
and 1 mM DTT. Pre-activating solution contained 100 mM BES, 1 mM
free Mg2+, 5 mM MgATP, 0.50 mM EGTA, 9.50 mM HDTA, 49.19 mM
potassium propionate, and 1 mM DTT. Maximal activating solution
(pCa 4.5), contained 75 mM BES, 1 mM free Mg2+, 5 mM MgATP,
10.00 mM EGTA, 10.01 mM CaCl2, 29.06 mM potassium propionate,
and 1 mM DTT. Pyruvate kinase and lactate dehydrogenase were
added to all three solutions prior to use at ﬁnal concentrations of
1 mg/ml and 0.1 mg/ml, respectively. Relaxing solution and maximal
activating solutions were then mixed to create experimental pCa
solutions ranging from pCa 6.4 to 4.5. All solutions had a ﬁnal ionic
strength of 180 mM and pH 7.0 at 20 °C. Solution compositions
were calculated by customized software based upon binding con-
stants described previously [35].
2.9. Data and statistical analysis
Tension-, stiffness, ATPase-, and ktr–pCa relationships were ﬁt
with a modiﬁed four parameter Hill equation: P=Po+axb/(cb+xb),
where P is the parameter of interest (tension, ATPase, ktr); Po is
the minimum value, a is the maximum value minus Po; x is pCa; b
is −e (Hill coefﬁcient); and c is the pCa at which 50% of maximum
value is reached (pCa50). ATPase–tension, stiffness–tension, and
ktr–relative tension (P/Po) relationships were ﬁt with linear curves.
All values are presented as mean±standard error of mean (SEM).
Data were analyzed using 2-way ANOVA, a Student–Newman–
Keuls post hoc method, with a level of statistical signiﬁcance set at
Pb0.05.
3. Results
3.1. Identiﬁcation of the cTnI S5/S6 phosphorylation site via LC–MS/MS
To identify novel sites of cTnI phosphorylation in mouse myocar-
dium that potentially play a role in the maladaptive functional
response, sarcomeric sub-proteomes were analyzed via LC–MS/MS.
A triply-charged precursor ion (m/z 649.5) corresponding to singly-
phosphorylated cTnI peptide (aa 2–20) was identiﬁed, and upon
fragmentation with CID, the phospho-site was identiﬁed as either S5
or S6 (Fig. 1). This site represents a novel phosphorylation site on the
unique mouse cardiac N-terminus of cTnI. S5/S6 phosphorylation was
identiﬁed in both wild type and in mice expressing active PKCε.
3.2. Chemo-mechanical measurements in skinned ﬁber bundles regulated
by control and pseudo-phosphorylated cTnI
In order to determine the functional role of phosphorylation at S5
and S6 of mouse cTnI, we designed recombinant cTn complexes and
exchanged them with endogenous cTn from skinned mouse papillary
muscle ﬁbers. Serines 5 and 6 of cTnI were pseudo-phosphorylated by
substitution with aspartic acid (S5D and S6D, respectively). Non-
phosphorylatable cTnI variants were generated by substitution of
alanine for serines 5 and 6 (S5A and S6A, respectively). Recombinant
cTnI proteins were incorporated into cTn complex containing myc-
tagged mouse cardiac TnT (myc-cTnT) and mouse cardiac cTnC.
Wild-type (Wt) and variant cTn complexes were then exchanged
into skinned mouse papillary muscle ﬁbers. As illustrated in Fig. 2,
this method resulted in an average exchange efﬁciency of 33–61% as
measured byWestern blot using cTnT-speciﬁc antibody. Exchange ef-
ﬁciency was determined as the ratio of the slower migrating cTnT
Fig. 1. Identiﬁcation of a novel phosphorylation site in cTnI. cTnI from Wt mice was digested and analyzed via LC–MS/MS on an LTQ mass spectrometer. CID fragmentation spectra
from both wild type (A) and PKCε (B) show a triply-charged, singly-phosphorylated precursor ion (m/z 649.5), which localizes the phosphorylation to either Ser-5 or Ser-6 in the
(ambiguity denoted by the parentheses). Observed a-, b- and y-ions with a relative abundance above 5% are labeled above each corresponding ion in the spectrum and are illus-
trated in the peptide sequence (top). Essentially identical results were obtained from heart samples from mice expressing active PKCε.
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was variability in exchange efﬁciency, but the variability was not
reﬂected in our measurements of tension, ATPase activity, or stiffness,
which demonstrated relatively small standard deviations (Figs. 3, 4).
The functional effects of cTnI variants were determined by simul-
taneously measuring tension, ATPase activity, and ktr over a range of
pCa values. The pCa–tension relation revealed a signiﬁcant decrease
in maximum tension in cTnI-S5A, -S6D, and -S6A-exchanged ﬁbers
compared to Wt-exchanged ﬁbers (Wt: Fmax=20.30±1.60 mN/mm2;
S5A: Fmax=15.25±0.84 mN/mm2, Pb0.01; S6A: Fmax=11.34±
0.37 mN/mm2, Pb0.01; S6D: Fmax=11.90±0.61 mN/mm2, Pb0.01;
Fig. 3A), with no signiﬁcant effect of S5D. The pCa–tension relation
showed increased Ca2+ sensitivity in the S5A-exchanged mutant
compared to Wt-exchanged ﬁbers (Wt: pCa50=5.76±0.04; S5A:
pCa50=5.93±0.04, Pb0.01), with no signiﬁcant effect of either S6A
or S6D. There were no effects of any of the mutations on the Hill coefﬁ-
cient of the pCa–tension relationship.
ATPase activity was measured at each pCa value via the rate of
decreasing UV absorption at 310 nm within the pCa solution duringFig. 2. Quantiﬁcation of cTn exchange in skinned ﬁber bundles. The exchange of endog-
enous for exogenous Wt or mutant cTn was determined by Western blot analysis from
skinned ﬁber samples using the cTnT-speciﬁc monoclonal antibody CT3. The difference
in migration of endogenous cTnT and exogenous myc-tagged cTnT (myc-cTnT)
allowed for the determination of the efﬁciency of exchange. Top: Representative
non-exchanged ﬁbers (NE) and an exchanged ﬁber (Ex). Bottom: Representative blot
of individual exchanged ﬁbers (Wt: lanes 3, 9; S5D: lanes 4, 8, 10; S5A: lane 5; S6D:
lane 6; S6A: lane 7) and recombinant cTn complex (Control: lanes 1, 2).tension development as described under “Methods” section. The
resulting pCa–ATPase activity relation (Fig. 3B) showed decreased
maximum ATPase activity in S5A-, S6A-, and S6D-exchanged ﬁbers
compared to Wt-exchanged ﬁbers (Wt: 183.2±4.7 pmol/s/mm3;
S5A: 152.5±3.3 pmol/s/mm3, Pb0.05; S6A: 136.7±3.4 pmol/s/mm3,
Pb0.01; S6D: 135.3±3.1 pmol/s/mm3, Pb0.01). The relationship be-
tween ATPase and tension (tension cost) showed no differences
among any of the variant- andWt-exchanged ﬁbers (Fig. 3C), indicating
no effect of any of the cTnI modiﬁcations on steady-state rate of
cross-bridge detachment. The pCa–ATPase activity relation demon-
strated a signiﬁcant decrease in the Hill coefﬁcient in S6A- and S6D-
exchanged ﬁbers compared to Wt-exchanged ﬁbers (Wt: nH=3.14±
0.35; S6A: nH=1.22±0.08, Pb0.05; S6D: nH=1.10±0.08, Pb0.05).
There was no effect of any of the variants on pCa50 of ATPase activity.
As summarized in the data shown in Fig. 4, the pCa–stiffness
relationship showed a decrease in maximal stiffness in S5A-, S6A-,
and S6D-exchanged ﬁbers compared to Wt-exchanged ﬁbers (Wt:
26.12±0.65; S5A: 19.94±0.45 arbitrary units (au), Pb0.05, S6A:
16.14±0.51 au, Pb0.01; S6D: 17.13±0.54 au, Pb0.01, Fig. 4A). The
decreased tension and stiffness of S5A-, S6A-, and S6D-exchanged
ﬁbers resulted in a normal stiffness to tension ratio, indicating no
effect of either mutation on the force generated per cross-bridge
(Fig. 4B). The pCa–stiffness relation also showed a decreased Hill
coefﬁcient with the S6A and S6D mutants compared to Wt (S6A:
nH=1.15±0.11; S6D: nH=1.08±0.11; Wt: nH=3.06±0.32).
At steady state for each pCa value, ﬁbers were subjected to a rapid
release re-stretch maneuver, resulting in disengagement of attached
cross-bridges. The measure of ktr reﬂects the sum of the rate-limiting
transition steps (ktr= f+g) of myosin cross-bridges to and from the
strongly-bound, force-generating state during isometric contraction.
We found ktr to be dependent on the pCa as previously reported
[36,37]. As recommended by Patel et al. [36], we expressed the rate of
force redevelopment as a function of relative isometric tension. ktr was
quantiﬁed at each pCa value by use of a single-exponential equation
Fig. 3. Tension– and ATPase–pCa relation in skinned ﬁber bundles exchanged with Wt
or mutant cTn. Tension–pCa relationship (A). ATPase–pCa relationship (B). Tension
cost (C). Tension– and ATPase–pCa relationships are presented as mean±SEM. n=8–10
ﬁbers, N=3–4 hearts. Tension cost is presented as the linear regression of mean data
from A and B.
Fig. 4. Stiffness–pCa relation in skinned ﬁber bundles exchanged with Wt or mutant
cTn. Stiffness–pCa relationship (A). Stiffness–tension relationship (B). Stiffness–pCa
relationship is presented as mean±SEM. n=8–10 ﬁbers, N=3–4 hearts. Stiffness–
tension relationship is presented as the linear regression of mean data from A and
Fig. 3A.
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linear relationship (Fig. 5A). The S6A and S6D mutations showed a
decreased slope of the ktr–P/Po relation compared to Wt (Wt: 16.65±
1.44 s−1; S6A: 9.45±0.95 s−1, Pb0.01, S6D: 9.03±1.13 s−1, Pb0.01,
Fig. 5B), indicating decreased number of cross-bridges entering into
force generating states in these variants.
3.3. In vitro studies on control of reconstituted myoﬁlaments by
cTnI-S5/6 variants
Data presented so far indicate that modiﬁcations at S6 signiﬁcant-
ly inhibit the actin–cross-bridge reaction. To address the mechanismof this modiﬁcation, we performed a series of experiments testing
whether modiﬁcations at S6 affect the ability of cTnI to inhibit the
actin–cross-bridge reaction. Data in Fig. 6A show that neither S6A
nor S6D inﬂuenced the ability of cTnI to inhibit actin–myosin interac-
tions. This ﬁts with our ﬁnding that the inﬂuence of modiﬁcations
at S6 alters the Ca-activated state of the myoﬁlaments. To examine
this possibility further, we investigated the inﬂuence of the modiﬁca-
tions at S6 on the ability of cTn to confer activation of the myoﬁla-
ments in the presence of Ca2+. In this same series we also tested for
interactions between cTnI-S6 variants and S23/S24, which are sub-
strates for PKA [9]. Data shown in Fig. 6B demonstrate cTnI-speciﬁc
phosphorylation, as determined by ProQ analysis, showing no differ-
ence in the amount of cTnI phosphorylation between groups. Data
illustrated in Fig. 6C show the results of ATPase measurements from
reconstituted myoﬁlament preparations regulated with increasing
concentrations of either control or S6 cTn, with and without PKA-
treatment. In Fig. 6C, the solid line shows the relation between
untreated cTn containing TnI–WT, –S6D, or –S6A and ATPase rate,
while the dashed lines show the relation of these cTn complexes
with ATPase rate following PKA-treatment. In the presence of Ca2+,
cTn complex containing TnI-S6D at 0.5 μM Tn (1:10 molar ratio of
Tm:actin) showed decreased ATPase activity compared to TnI–Wt
reconstituted myoﬁlaments (0.14±0.02 vs. 0.29±0.02 s−1, Pb0.01,
Fig. 6C). There was no difference between the ATPase activity of
preparations controlled by either cTn–TnI–S6A or cTn–TnI–Wt at
Fig. 5. ktr–relative tension relationship in skinned ﬁber bundles exchanged with Wt or mutant cTn. Average ktr–relative tension plots from each experimental group (A). Slope of
ktr–relative tension between ﬁbers exchanged with Wt and mutant cTn (B). ktr–relative tension are presented as the linear relationship of ktr and relative tension. Slope of ktr–relative
tension relationships is presented as mean±SEM (B). n=5–10 ﬁbers, N=3–4 hearts. **Pb0.01 compared to Wt.
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ence in ATPase activity between myoﬁlaments reconstituted with cTn
containing either S6 variant orWt cTnI (gray lines, Fig. 6C). Treatment
of TnI–Wt with PKA prior to incorporation into Tn complex showed
signiﬁcant inhibition of ATPase activity compared to untreated cTn–
TnI–Wt myoﬁlaments ([Tn]=1.0 μM: 0.04±0.01 vs. 0.36±0.04 s−1,
Pb0.01). Troponin complex containing PKA-phosphorylated TnI–S6D
or –S6A also showed PKA-induced inhibition of ATPase activity com-
pared to their respective untreated groups ([Tn]=1.0 μM; S6D:
0.10±0.01 vs. 0.32±0.02 s−1, Pb0.01, S6A: 0.15±0.022 vs. 0.44±
0.02 s−1, Pb0.01). However, PKA-treatment had a reduced effect on
inhibiting ATPase activity in Tn containing TnI–S6 variants compared
to PKA-treated TnI–Wt ([Tn]=1.0 μM; S6D: 0.10±0.01 vs. 0.04±
0.01 s−1, S6A: 0.15±0.02 vs. 0.04±0.01 s−1, Pb0.05).
3.4. An A2V mutation in the acidic region of cTnI and linked to dilated
cardiomyopathy has altered binding to thin ﬁlaments and to cTnC
In view of data demonstrating the potential of the acidic region of
cTnI to inﬂuence myoﬁlament function via structural and charge
changes, we sought to determine whether other signiﬁcant modiﬁca-
tions in this region might affect myoﬁlament function. We focused on
an A2V mutation linked to DCM in order to provide more support for
the signiﬁcance of these cTnI residues. Murphy et al. [20] reported
that the A2V mutation caused a signiﬁcant impairment in the interac-
tion between cTnI and cTnT using a heterologous cell system. Howev-
er, virtually nothing is known about whether and how this mutation
alters myoﬁlament regulation or the response to β-adrenergic stimu-
lation. We therefore determined the functional effects of the cTnI A2V
mutation on myoﬁlament regulation and myoﬁlament response to
PKA phosphorylation. To determine the effects of the A2V mutation
and PKA pseudo-phosphorylation (S23D/S24D) on cTnI inhibitory
activity, we measured actin–Tm–S1 ATPase activity as a function of
cTnI concentration in the absence of Ca2+. Fig. 7A shows averaged
percent maximum ATPase activity for each form of cTnI. Maximum
inhibition occurred near a 1:1 actin:TnI ratio, but the extent of inhibi-
tion was signiﬁcantly less for cTnI–A2V as compared to Wt at all
concentrations studied (all concentrations Pb0.05, Fig. 7A). Alone,
cTnI–S23D/S24D demonstrated the same inhibition as Wt, which
was also similar to the inhibition by cTnI–A2V/S23D/S24D. The
lower inhibitory activity of cTnI–A2V was restored to that of Wt by
pseudo-phosphorylation at S23/S24.
Wemeasured ATPase activity as a function of TnC:TnI ratio to deter-
mine the effects of the A2Vmutation and PKA pseudo-phosphorylation
on the Ca–TnC as amethod to probe the Ca-dependent cTnC–cTnI inter-
actions. Fig. 7B shows averaged percent maximum ATPase activities at
pCa 4.5 as a function of varyingmolar ratios of cTnC:cTnI. Myoﬁlamentscontrolled by either Wt or cTnI–S23D/S24D showed a similar increase
in ATPase rate with increasing molar ratios of cTnC:cTnI. However,
compared to these controls, the ability of cTnC to reverse inhibition
by cTnI–A2V was signiﬁcantly depressed (all concentrations Pb0.05,
Fig. 7B). Moreover, at all ratios, cTnC reversed inhibition by cTnI–A2V/
S23D/S24D to a lower extent than cTnI–A2V (all concentrations Pb
0.05). These results indicate that in this assay the A2V mutation
decreases the afﬁnity of the TnI regulatory region for TnC, and PKA
pseudo-phosphorylation further decreases the afﬁnity in the presence
of the A2V mutation.
3.5. Myoﬁlaments regulated by cTn–A2V demonstrate altered cooperativity
and kinetics of force redevelopment (ktr) dependent on pseudo-
phosphorylation of S23/S24
To determine the effects of the A2V mutation and PKA pseudo-
phosphorylation onmyoﬁlamentmechanical properties, we exchanged
Tn containing cTnI–Wt, A2V, S23D/S24D, and A2V/S23D/S24D into
skinned left ventricular papillary ﬁber bundles. Data in Fig. 8 show
tension–pCa relations from each group and demonstrate that Ca2+
sensitivity (pCa50) of steady state tension and maximum tension of
skinned ﬁber bundles regulated by cTnI–A2V were the same as the
controls (Wt: Fmax=26.7±0.9 mN/mm2; A2V: Fmax=23.0±
1.5 mN/mm2; Wt: pCa50=5.71±0.02; A2V: pCa50=5.70±0.02,
Fig. 8A). However, in ﬁbers regulated by the cTnI–A2V mutation
alone, there was a signiﬁcantly decreased Hill coefﬁcient (nH), a
measure of the cooperativity of tension activation (Wt: nH=
4.18±0.10; A2V: nH=3.77±0.10, Pb0.01). cTnI–S23D/S24D caused a
signiﬁcant desensitization of the tension–pCa relation as previously
demonstrated [38] in the presence or absence of the A2V mutation
(Wt: pCa50=5.71±0.02; S23D/S24D: pCa50=5.55±0.02, Pb0.01;
A2V/S23D/S24D: pCa50=5.53±0.03, Pb0.01), with no effect on max-
imum tension or nH.
Fig. 8B shows results of experiments in which we determined
ATPase rate of the skinned ﬁber bundles. We found that in ﬁbers
controlled by cTnI–A2V there was no effect on the Ca2+ sensitivity
of ATPase activity, the Hill coefﬁcient of the ATPase activity–pCa
relation, or the maximum ATPase activity. Pseudo-phosphorylation,
whether in the absence or presence of the cTnI–A2V mutation,
induced a rightward shift of the ATPase activity–pCa relation when
compared to Wt (Wt: pCa50=5.70±0.02; S23D/S24D: pCa50=
5.55±0.03, Pb0.01; A2V/S23D/S24D: pCa50=5.54±0.03, Pb0.01),
consistent with previous studies, but did not signiﬁcantly alter other
parameters. We also analyzed the ATPase activity–tension relation,
or tension cost (Fig. 8C). We found that the cTnI–A2V mutation
alone did not alter the relation compared to Wt (Wt: 5.15±0.21;
A2V: 5.25±0.40). In contrast, cTnI–S23D/S24D and cTnI–A2V/S23D/
Fig. 6. Wt- and mutant-cTn effects on actin–Tm–S1 ATPase activity. All assays
contained 7 μM actin, 0.4 μM tropomyosin and 0.2 μM myosin S1, with ﬁnal buffer
conditions of 35 mM NaCl, 5 mM MgCl2, and 20 mM MOPS, pH 7.0. Wt- and mutant
cTnI inhibition of ATPase activity (A). Wt- and mutant-cTn effects on ATPase activity
in the presence (black lines) and absence (gray lines) of Ca2+ (C). Relative
PKA-dependent phosphorylation of TnI between Wt, S6A, and S6D Tn complexes (B).
ATPase activity was calculated by subtracting the ATPase activity of myosin S1 only
at each concentration. Data presented as mean±SEM. n=3–4. **Pb0.01.
Fig. 7. Wt- and mutant-cTn effects on actin–Tm–S1 ATPase activity. Wt and mutant
cTnI inhibition of ATPase activity (A). All assays contained 6 μM actin, 1 μM tropomy-
osin and 0.5 μM myosin S1, with ﬁnal buffer conditions of 10 mM NaCl, 5 mM MgCl2,
and 20 mM MOPS, pH 7.0. Wt- and mutant cTnI inhibition of ATPase activity (A). Ef-
fects of increasing ratio of cTnC to Wt- and mutant cTnI- on ATPase activity in the pres-
ence of Ca2+ (pCa 4.0). Percent maximal ATPase activity was calculated by subtracting
the ATPase activity ofmyosin S1 only and dividing by ATPase activity at zero cTnI (Fig. 7A)
and at zero cTnC (Fig. 7B). Data presented as mean±SEM. n=4–6. *Pb0.05.
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parts (Wt: 5.15±0.21; S23D/S24D: 6.18±0.48, Pb0.01; A2V/S23D/
S24D: 6.68±0.47, Pb0.01). These results indicate that PKA pseudo-
phosphorylation increases the rate of cross-bridge detachment,
which has previously been reported [38].
To further investigate rate constants for the cross-bridge reactions,
we measured ktr as a function of pCa and of relative tension. Fig. 9Adepicts representative ktr–relative tension relations for each group
and shows that the cTnI–A2V mutation signiﬁcantly decreased the
slope (Wt: 8.39±0.50; A2V: 6.82±0.50, Pb0.01, Fig. 9B) and signiﬁ-
cantly increased the y-intercept of the relationship (Wt: 3.91±0.31;
A2V: 5.67±0.58, Pb0.01) as compared to Wt, whereas both PKA
pseudo‐phosphorylation variants were similar to Wt. These results
indicate that the A2Vmutation increases the kinetics of force redevel-
opment at sub-maximal, but not maximal Ca2+ levels.
4. Discussion
Our results provide the ﬁrst evidence of a functional signiﬁcance
of conformational changes and novel sites of phosphorylation at the
acidic region of the unique N-terminus of cTnI. Our ﬁndings also
extend understanding of potential control of cardiac function by the
N-terminus of cTnI physiological and patho-physiological states. It is
apparent from our results that these conformational and charge
induced modulations are potentially signiﬁcant factors in acquired
and familial cardiomyopathies. While carrying out the present stud-
ies, we became aware of a report by Zhang et al. [19] identifying
cTnI–S5/S6 in human myocardium and demonstrating a decrease in
phosphorylation of these sites in samples from hearts in failure.
Fig. 8. Tension– and ATPase–pCa relation in skinned ﬁber bundles exchanged with Wt
or mutant cTn containing cTnI–A2V. Tension–pCa relationship (A). ATPase–pCa rela-
tionship (B). Tension cost (C). Tension– and ATPase–pCa relationships are presented
as mean±SEM. n=11–19 ﬁbers, N=4–8 hearts. Tension cost is presented as the lin-
ear regression of mean data from A and B.
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study. In view of our data showing a depression in maximum tension
with S6D substitution (Fig. 3A), decreased phosphorylation of this
site in human heart failure may be compensatory. Our studies involv-
ing LC–MS/MS identiﬁed the Ser-5/-6 in both wild type and the PKCε
over-expressing mouse model, a known model of DCM [21]. The
development of DCM in these mice has been attributed to decreasedCa-sensitivity, most notably through phosphorylation of cTnI at
S43/S45 and T144 [39,40]. Modiﬁcation at these sites depressesmyo-
ﬁlament response to Ca2+ and maximum tension development [39].
Although the kinases involved in modiﬁcation of these novel sites
are unknown, bioinformatic analysis of cTnI (NetPhosK, Technical
University of Denmark) shows a relatively high score for the involve-
ment of Ca/calmodulin-dependent kinase II (CaMKII) (Ser-5: 0.58 and
Ser-6: 0.61). However, to determine whether phosphorylation levels
at cTnI–S5/S6 are different in PKCε over-expressing hearts, as well as
the kinase or kinases responsible for phosphorylation of these sites
requires future quantitative analysis.
Our data demonstrate that pseudo-phosphorylation of cTnI–S6 in
the acidic domain of the N-terminus induces a depressed maximum
tension development of skinned ﬁber preparations with no apparent
change in the stiffness/tension ratio or cross-bridge detachment rate,
but a reduction in the number of cross-bridges entering into force
generating states. The particular sensitivity of activation of tension
to modiﬁcation of cTnI–S6 is emphasized by our data demonstrating
little or no effects of cTnI–S5D or cTnI–S5A, but signiﬁcant of effects
cTnI–S6D and cTnI–S6A. We think that the mechanism for these
effects may involve an intra-molecular interaction, as described above,
between the acidic region containing cTnI–S6, and regulatory domains
surrounding the Ip of cTnI. Our proposal is that when cTnI–S6 is phos-
phorylated or conformationally modiﬁed, the interaction of the SwP
and the acidic region of cTnI impedes release of the SwP/Ip region
from actin, and therefore induces a reduction in the number of cross-
bridges entering into the force generating cross-bridge cycle. There
was no effect of cTnI–S6D on the inhibitory effect of cTnI (Fig. 6A), indi-
cating that reaction with the Ip or a second actin binding region may be
important in the inhibition of tension. Other evidence also indicates the
functional signiﬁcance of the acidic region of cTnI. Studies [17] have
been carried out a on a mutant cTnI truncated by removal of the acidic
region (cTnI(Δ2-11)). Compared to controls, hearts of transgenic mice
expressing the mutant demonstrated signiﬁcantly depressed contrac-
tion and relaxation kinetics as well as decreased maximal tension in
skinned ﬁbers with no inﬂuence of the mutation on Ca-sensitivity or
phosphorylation at cTnI–S23/S24. Solution NMR studies indicated that
residues 2–11 do not inﬂuence the induction of the open state of
cTnC. In contrast to the studies [17] with cTnI(Δ2-11) in which there
was no apparent inﬂuence of removal of the acidic region on PKA effects
on themyoﬁlaments we found thatmodiﬁcation at cTnI–S6 suppressed
the effect of PKA phosphorylation of cTnI to inhibit activation. Thus,
modiﬁcations at Ser-6 appear to affect mechanisms by which PKA-
dependent phosphorylation of cTnI–S23/S24 suppresses response to
Ca2+.
Our data indicate a role for cTnI–S6 and cTnI–A2 in modulating the
molecular conformation of cTnI and for allosteric interactions with
other regions of the cTnI N-terminal peptide. There were signiﬁcant
depressions in tension induced by both Asp and Ala substitutions at
cTnI–S6, which indicates that conformational changes as well as
charge changes inﬂuence the function of the cTnI acidic region. The
demonstration of signiﬁcant effects of the conservative substitution
of Val for Ala in the DCM linked mutation also indicates the sensitivity
of this region to conformational modulation affecting myoﬁlament
response to Ca2+ in the form of an altered cooperativity of activation.
Moreover the loss of this effect when cTnI–S23/S24 are pseudo-
phosphorylated further indicates the allosteric inﬂuence of modiﬁca-
tions of the acidic region of the cTnI on the phosphorylation motif at
S23/S24. Although an obvious limitation to this study is that our
control variant (S6A) had similar results to that of our test variant
(S6D), there is evidence that Ala substitution is not a silent substitu-
tion. In similar studies to those shown here, it was reported that
substitution of S23/S24 of cTnI with either Ala or Asp both reduced
maximal tension and ATPase activity, due to a decrease in the number
of reacting crossbridges [41]. These effects are similar to those dem-
onstrated by another actin-binding protein, calponin [42]. In this
Fig. 9. ktr–relative tension relationship in skinned ﬁber bundles exchanged with Wt or mutant cTn containing cTnI–A2V. Average ktr–relative tension plots from each experimental
group (A). Slope of ktr–relative tension between ﬁbers exchanged with Wt and mutant cTn (B). ktr–relative tension are presented as the linear relationship of ktr and relative ten-
sion. Slope of ktr–relative tension relationships is presented as mean±SEM (B). n=5–8 ﬁbers, N=3–5 hearts. *Pb0.01 compared to Wt.
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induced the same alteration in afﬁnity of calponin for actin. It is inter-
esting that as with the cTnI-N terminus, calponin is a highly ﬂexible
protein, contributing to the idea that alterations in critical structural
sites can alter protein function. We think that in the case of cTnI
conformational modulation of the highly ﬂexible N-terminus pro-
vides a mechanism of altered direct and allosteric interactions with
neighbors, and in the case of the acidic region with intra-molecular
regions of cTnI especially the SwP [15]. Overall our data indicate
that modiﬁcations at the acidic region may inﬂuence diverse func-
tional properties of the myoﬁlaments in a manner not previously
appreciated.
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